Specialty Pharmacy

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (DTCA), with the likely exception being drug pricing. Despite criticisms and the heated debate on the appropriateness of this channel, DTCA spending continues to grow. The drug industry spent approximately $5.6 billion on ...

One of the more vexing and troubling public health policy issue that has plagued the US pharma industry, yet receiving less deserving public news coverage than other industry stories, has been the existence of chronic drug shortages since the turn of the 21st century. A drug shortage is defined in which the “total supply of all clinically interchangeable versions of an FDA-regulated drug is ...

The pharmaceutical industry is undergoing a significant transformation - shifting away from the development of blockbuster drugs to a more value-driven approach based, increasingly, on specialty medicines for niche markets and patient outcomes. For the commercial operations landscape, specialty medicines come with their own specific challenges across data integration and data coverage. Further, ...

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about the sustainability of increasing sales revenue mainly through pricing. Further, given the cost of newer specialty medicines, performance-based pharmaceutical pricing contracts through payers will become the norm. The ...

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in ...

The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift has also brought significant challenges, especially in the form of pricing and market access in an environment that is becoming increasingly resistant to higher cost drugs. This paper looks at the keys to success on ...